B2M and rhabdomyosarcoma: In addition, B2M LOH (without CN-LOH, LOH+gain or amplification) was detected in 18 (3.9%) tumors, including six (11.8%) rhabdomyosarcoma cases (Figures 9, 10; Supplementary Table S12C).